Matthew R. Mcbrady Sells 400 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Matthew R. Mcbrady sold 400 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $718.40, for a total transaction of $287,360.00. Following the completion of the sale, the director now owns 3,492 shares of the company’s stock, valued at $2,508,652.80. This trade represents a 10.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Down 0.0%

Shares of NASDAQ AXON opened at $728.39 on Friday. The business has a 50-day moving average price of $580.48 and a 200 day moving average price of $591.44. The stock has a market cap of $56.71 billion, a PE ratio of 188.21, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a 52-week low of $273.52 and a 52-week high of $732.22.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. Axon Enterprise’s quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.15 earnings per share. Equities research analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Paragon Private Wealth Management LLC acquired a new stake in shares of Axon Enterprise in the first quarter valued at approximately $298,000. Federation des caisses Desjardins du Quebec increased its stake in Axon Enterprise by 10.8% during the first quarter. Federation des caisses Desjardins du Quebec now owns 7,627 shares of the biotechnology company’s stock worth $4,011,000 after acquiring an additional 746 shares during the last quarter. Atreides Management LP purchased a new position in Axon Enterprise in the first quarter valued at approximately $33,083,000. Alamea Verwaltungs GmbH purchased a new position in shares of Axon Enterprise in the 1st quarter valued at $218,000. Finally, Baird Financial Group Inc. boosted its position in shares of Axon Enterprise by 5.9% in the first quarter. Baird Financial Group Inc. now owns 5,987 shares of the biotechnology company’s stock worth $3,149,000 after buying an additional 333 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AXON. Northcoast Research lowered Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Needham & Company LLC lifted their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Barclays increased their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. The Goldman Sachs Group lifted their target price on Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Craig Hallum cut shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $652.73.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.